GMR
The Original

DESIGN AND MOLECULAR CHARACTERIZATION OF BIOACTIVE HETEROCYCLIC COMPOUNDS AS POTENTIAL MODULATORS OF GENETIC SIGNALING PATHWAYS

Dr. Disha Tilala[1], Dr. Preeti Nand Kumar[2], Anil Kumar Singh[3], Dr. Pratibha Suresh Kurup[4], Sonali[5], KavitaPatel[6]

[1]Assistant professor, Vishwakarma Government Engineering College, Email: dishatilala10@gmail.com, ORCID ID:0009-0006-9396-300X
[2]Associate Professor, Department of Chemistry, Christian College of Engineering and Technology, Bhilai, Chattishgarh,
Mail id -nandinipreeti@gmail.com
[3]Department of Chemistry, Teerthanker Mahaveer University, Email I'd: dr.anilkumarsingh2009@gmail.com, Orcid I'd: 0000-0003-2933-4058
[4]Professor, Department of chemistry, Rungta International Skill University, Bhilai, Chattishgarh, Email Id: pratibha.sureshkurup@rungta.org
[5]Assistant professor, Centre for research and innovations, AGC, AMRITSAR, Email ID: sonalisharma2190@gmail.com
[6]Associate Professor, Chemistry, Organic Chemistry, O P Jindal University Raigarh Chhattisgarh, Email Id: kavita.patel@opju.ac.in, Orcid id: 0000-0002-1245-3395

ABSTRACT
Heterocyclic compounds are central to medicinal chemistry because their structural diversity, tunable physicochemical properties, and capacity for selective molecular interactions enable modulation of protein and nucleic acid-associated processes. Despite rapid advances, the field remains fragmented across synthetic chemistry, computational modeling, molecular characterization, signaling biology, and translational pharmacology, limiting integrated interpretation of structure–activity relationships and pathway-level effects. This review critically examines the design, synthesis, characterization, and biological evaluation of bioactive heterocycles as modulators of genetic signaling pathways. Evidence was synthesized from contemporary literature covering nitrogen-, oxygen-, and sulfur-containing, fused, and polycyclic scaffolds; structure-based design; docking and molecular dynamics; spectroscopy and crystallography; and pathway-focused biological studies. The analysis indicates that heterocyclic frameworks can regulate PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, JAK/STAT, Wnt/β-catenin, NF-κB, p53, and related networks through kinase inhibition, transcriptional control, epigenetic modulation, and nucleic acid interactions. Integrated computational and experimental characterization improves target recognition, selectivity, and mechanistic validation, although pathway redundancy, off-target effects, resistance, limited bioavailability, and incomplete translation remain major constraints. Future progress will depend on combining artificial intelligence, multi-omics, CRISPR-based validation, biomarker-guided strategies, and precision delivery to develop safer, selective, and clinically relevant heterocyclic signaling modulators. These findings support a chemistry-to-signaling framework linking molecular architecture, target engagement, gene regulation, cellular phenotype, and therapeutic potential.

KEYWORDS: Bioactive heterocycles; Genetic signaling; Medicinal chemistry; Molecular characterization; Structure-based drug design

INTRODUCTION
The heterocyclic compounds represent one of the most important structural classes in medicinal chemistry due to their wide chemical diversity, tunable physicochemical properties, and capacity for selective interaction with biological macromolecules. These compounds are defined by the presence of one or more heteroatoms, typically nitrogen, oxygen, or sulphur, in a ring structure and can be monocyclic, fused, bridged, or polycyclic [1]. Heterocycles containing nitrogen, oxygen, and sulfur are also very important for biologically active molecules, and some of these scaffolds are represented by pyridines, pyrimidines, imidazoles, pyrazoles, triazoles, quinazolines, quinolines, indoles, benzimidazoles, and others [2] that are explored extensively in therapeutic optimization. Their role in drug discovery is closely linked to their ability to form hydrogen bonds, interact with aromatic residues, influence electronic distribution, participate in ionization processes, confer conformational rigidity, affect lipophilicity, influence aqueous solubility, and influence metabolic stability [3]. All of these properties directly affect the recognition of the ligand, affinity for the target, membrane permeability, pharmacokinetic profile and biological activity.
The conceptual framework of therapeutic drug development has been greatly altered by advances in molecular biology and genomic medicine. The understanding of human diseases is shifting from being the result of abnormal proteins or genes, to abnormal perturbations in interconnected molecular and genetic signaling networks. All of these cell-surface receptors, intracellular kinases, transcription factors, epigenetic regulators, ubiquitin-dependent systems, and non-coding RNAs control gene expression, cell proliferation, differentiation, metabolism, immune response, survival, and programmed cell death [4]. These signaling systems are dysregulated in the initiation and/or progression of cancer, inflammatory and autoimmune diseases, neurodegenerative diseases, cardiovascular diseases, metabolic disorders, and several infectious diseases [5]. Phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin

(PI3K/AKT/mTOR), RAS/RAF/MEK/ERK, Janus kinase/signal transducer and activator of transcription (JAK/STAT), Wnt/β-catenin, nuclear factor kappa B (NF-κB), transforming growth factor-beta (TGF-β)/SMAD, Notch, Hedgehog, and Hippo/YAP–TAZ are thus major targets for drug development.

Heterocyclic compounds are especially well suited for modulation of such pathways, as relatively small structural changes can dramatically affect the molecular recognition, potency, selectivity, and intracellular activity. Heterocyclic structures can be designed to interact with a protein kinase's nucleotide pocket, disrupt receptor-mediated signaling, disrupt protein–protein interactions, modulate the activity of transcription factors, and inhibit chromatin-remodeling and epigenetic-modulating enzymes [7]. These molecular interactions can alter phosphorylation cascades, protein localization, activation of transcription factors, DNA-binding activity, and downstream gene-expression programs [8]. The relevance of certain heterocyclic structures to pharmacological activity is not limited to the interaction with proteins, as they can also interact directly with nucleic acids, which can occur as a result of intercalation within the DNA structure, binding in the grooves, stabilization of G-quadruplexes, or recognition of structured RNA motifs [9].

Epigenetic and post-transcriptional mechanisms are also affected by heterocyclic compounds' influence on genetic regulation. Modulators of DNA methyltransferases, histone deacetylases, histone methyltransferases and demethylases, bromodomain proteins, RNA-associated regulatory proteins, and ubiquitin–proteasome components have been explored as small heterocyclic molecules that regulate DNA methylation. A modulation of these targets may affect chromatin accessibility and transcriptional programs without the change of the underlying DNA sequence and offers opportunities for the reversal of pathological gene-expression states. These mechanisms are especially important in cancer, drug resistance, chronic inflammation, and conditions with long-term dysregulated transcription and/or epigenetics.

Modern heterocyclic drug discovery has evolved from an empirical synthetic platform to rational and mechanism-oriented molecular design. In the case of structurally or genetically defined targets, systematic optimization of compounds can be achieved using structure-based drug design, scaffold hopping, bioisosteric replacement, molecular hybridization, pharmacophore modeling, fragment-based discovery, quantitative structure–activity relationship analysis, molecular docking, and molecular dynamics simulations. This can then be used to identify the biological effects of predicted molecular interactions in pathways through experimental technologies such as transcriptomics, proteomics, phosphoproteomics, epigenomics, gene-editing approaches, and functional genomic screening [12]. Incorporation of these techniques is gradually enhanced with the aid of synthetic intelligence, machine learning, network pharmacology, and multi-omics evaluation, where one can assess a molecule's chemical structure, target engagement, pathway disruption, toxicity, and even systems-level responses within biology [13].

Despite the success of such transformations, there are still many problems to overcome in order to realize structurally interesting heterocycle-to-signal molecule conversions of therapeutic relevance. The ability of a compound to bind to a docking target or be enzymatically active does not guarantee intracellular target engagement, pathway selectivity, transcriptional effects, or therapeutic efficacy. Translation success can be significantly limited by signaling redundancy, feedback regulation, activation of compensatory pathways, molecular heterogeneity, off-target pharmacology, unfavorable absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties, and acquired resistance [13]. A holistic understanding of the link between heterocyclic molecular structure and target recognition, signaling-network modulation, gene-expression control, cellular phenotype, pharmacological activity, and therapeutic efficacy is thus crucial for designing future bioactive compounds.

Objective of the Review

The objective of this review is to critically synthesize the latest advancements in the design, synthesis, molecular characterization, and biological evaluation of bioactive heterocyclic compounds as modulators of genetic signaling pathways. Special focus is given to structure–activity relationships, molecular targets, signaling and epigenetic mechanisms, computational and multi-omics approaches, therapeutic applications, resistance mechanisms, and new strategies for precision drug development.

REVIEW

Fundamental Principles of Heterocyclic Molecular Design

Electronic, steric, conformational, and physicochemical parameters, which reflect the ability of heterocyclic compounds to interact with molecular targets, determine the biological performance. Aromaticity is a fundamental structural characteristic, and π-electrons can be delocalized to provide increased stability and promote π–π stacking with aromatic residues in protein-binding pockets or the structure of DNA [13]. The number, kind, and location of the heteroatoms further define the electron density, dipole moment, protonation state, and hydrogen bonding ability, which in turn define the target recognition and orientation of the ligand. The nitrogen atoms in the heterocycles are particularly versatile as they could act as hydrogen-bond acceptors, metal coordinating sites, or could be protonated under physiological conditions [14].

Complementarity of molecules depends on many different factors, including hydrogen-bond donor and acceptor patterns. The strategic positioning of heteroatoms can enhance interactions with catalytic residues, protein kinase hinge regions, receptor binding, and/or proteins that bind to DNA [15]. Hydrophobic and van der Waals interactions also provide extra binding energy, and aromatic substitution can provide additional nonpolar interactions with target proteins. The molecular polarity should be optimized, as too high a polarity could result in impaired permeability of the membrane and too low a polarity could lead to decreased aqueous solubility and nonspecific binding.

Another principle of heterocycle drug design is conformational restriction. Rigid scaffolds can eliminate the entropic penalty due to the conformational changes required for target binding and keep the substituents in desirable 3D structures

[16]. In addition, steric modification around the heterocyclic nucleus can help to increase selectivity to avoid binding to structurally similar off-target proteins. Ionization, lipophilicity, molecular size, and topological polar surface area all play a role in the absorption, intracellular distribution, and pharmacokinetic properties [17]. The properties of these scaffolds can be rationally manipulated to achieve the simultaneous optimization of drug-like properties, metabolic stability, signaling selectivity, and target affinity.

Nitrogen-Containing Heterocycles as Privileged Bioactive Scaffolds

Nitrogen-containing heterocycles are one of the most common structural features in medicinal chemistry, as they have the ability to interact with a wide range of biological targets through strong and highly directional interactions due to their electronic versatility. In particular, pyridine and pyrimidine rings are known to be useful in the design of kinase inhibitors, as the ring N atoms can mimic hydrogen-bonding interactions related to the recognition of endogenous nucleotides and can be involved in efficient interactions with conserved residues of the hinge region [18]. Pyrimidine-containing scaffolds have thus been used in many receptor and intracellular kinase inhibitors which target proliferation, survival, angiogenesis and inflammatory signalling.

Other derivatives of imidazole, pyrazole, triazole, and tetrazole offer other ways to modulate electronic distribution, hydrogen bonding, metal coordination and metabolic stability. Imidazole can bind to metalloproteins and catalytic residues, while the triazole ring frequently serves as a metabolically stable linker or a pharmacophoric group which can help to retain a favourable molecular geometry [19]. Quinazoline derivatives have been of special interest as receptor tyrosine kinase modulators, such as epidermal growth factor receptor-associated signaling, due to their high affinity occupancy of the adenosine triphosphate binding regions [20].

The quinoline, isoquinoline, indole, and benzimidazole scaffolds have wider pharmacological versatility. They possess fused aromatic architectures that enable π–π interaction with protein residues and nucleic acid bases and allow for multiple positions for functional substitution. In particular, indole derivatives are of great interest because the indole nucleus has structural elements common to endogenous signaling molecules and can interact through hydrogen bonding and hydrophobic interactions [21]. Purine and purine-like heterocycles also take advantage of structural homology with endogenous nucleotides, allowing modulation of kinases, metabolic enzymes, and nucleotide-sensitive regulatory proteins. Nitrogen heterocycles are thus privileged structures for the design of selective modulators of genetic signaling pathways [22] due to their chemical adaptability. Figure 1 presents some of the key nitrogen-containing heterocyclic frameworks.



Figure 1. Major Nitrogen-Containing Heterocyclic Scaffolds

Oxygen- and Sulfur-Containing Heterocyclic Systems

Heterocycles containing oxygen and sulfur atoms increase the structural and electronic possibilities for the creation of bioactive signaling modulators. Furans, benzofurans, chromenes, coumarins, and systems related to flavonoids, which are all scaffolds containing oxygen, present good combinations of aromaticity, polarity, and hydrogen-bond-accepting capacity. They are able to interact with the catalytic residues and recognition sites of enzymes, receptors, and transcription-associated proteins and affect the distribution of electrons and the dipole properties of molecules [23]. Fused-ring architectures have been investigated in several pharmacological areas, since benzofuran and chromene derivatives were found to acquire increased molecular rigidity and thus are able to better position themselves in hydrophobic target pockets. Molecules that contain the coumarin nucleus form an extremely versatile class of oxygen heterocycles. Structural substitution around the benzopyrone core may modify the antioxidant, anti-inflammatory, antiproliferative, and enzyme-

modulatory activity, which can consequently modify the pathways that are linked to oxidative stress, inflammation, and cell survival [24]. Flavanoid-type heterocycles also show the ability to target several intracellular signaling proteins but with a much larger spectrum of targets, which has to be assessed carefully for their selectivity and pharmacokinetic properties.

Thiophenes, thiazoles, benzothiazoles, and thiadiazoles are sulfur-containing heterocycles that exhibit unique polarizability and electronic properties that could enhance interactions in hydrophobic or electronically matched binding pockets [25]. The thiazole and benzothiazole classes of compounds have had many studies conducted as kinase inhibitors, antimicrobials, and regulators of proliferative signaling. A change of oxygen or carbon to a sulfur atom may alter binding orientation, metabolic stability, molecular volume, and lipophilicity [26]. The presence of such heteroatom substitutions could offer a rationalized approach to optimize the potency, yet retain desirable drug-like properties. The oxygen and sulfur systems can thus be used as complementary pharmacophoric scaffolds to modulate enzymes, receptors, transcription regulators and signaling proteins involved in pathological gene-expression programs [27].

Fused and Polycyclic Heterocyclic Scaffolds

Fused and polycyclic heterocyclic systems are becoming significant in molecular design due to the ability to fuse to significantly affect molecular rigidity, target selectivity, binding orientation, and pharmacokinetic properties. The conformational restriction created by fusion of two or more aromatic or partially saturated rings can be beneficial by decreasing the rotational freedom of molecules and may preorganize pharmacophoric groups into orientations that are conducive to target engagement [28]. This property is especially useful when targeting specifically defined protein cavities, kinase active sites or protein–protein interaction surfaces, where the complementarity is of a 3D nature.

The fused heterocycles like quinazolines, quinolines, benzimidazoles, benzothiazoles, indoles and triazolopyrimidines provide tremendous opportunities for structural modifications. They display extended aromatic surfaces for hydrophobic contacts and π–π interactions, and the judicious placement of heteroatoms allows for hydrogen-bonding sites for better recognition of specific amino acid residues [29]. Rigidity of the scaffolds can also be increased to enhance the binding affinity by minimizing the loss of conformational entropy during association of the ligand. However, over-fused products can have enhanced lipophilicity and reduced aqueous solubility, and may bind to non-specific proteins, so the polarity and ionisation properties of substituents need to be carefully optimized.

Scaffold fusion may also have a role in regulating membrane permeability and metabolic stability. Metabolically labile positions can be blocked by ring fusion, while the addition of polar substituents can account for the increased hydrophobic surface area [30]. Therefore, inhibitors based on fused heterocycles are often used in the development of inhibitors of kinases, epigenetic enzymes, proteins associated with DNA, and transcription regulators [31]. They can also be structurally complex enough to allow interaction with several subpockets of a target, which may lead to greater potency and potentially selectivity, in some cases. The intentional design of fused and polycyclic heterocycles thus offers an exciting strategy to produce high-affinity modulators of signaling pathways, while simultaneously ensuring appropriate molecular rigidity, permeability, solubility, and pharmacokinetics [32]. Active heterocycles and their key structural features for target recognition and modulation of signaling pathways are listed in Table 1.

Table 1. Major Heterocyclic Scaffolds and Their Molecular Characteristics

Heterocyclic class	Representative scaffolds	Key molecular feature	Major biological relevance
Nitrogen-containing	Pyridine, pyrimidine, imidazole, quinazoline, indole	Strong H-bonding and target recognition	Kinase and transcriptional regulation
Oxygen-containing	Furan, benzofuran, coumarin, chromene	Polarity and electronic modulation	Oxidative, inflammatory, and proliferative signaling
Sulfur-containing	Thiophene, thiazole, benzothiazole	High polarizability and lipophilicity	Enzyme and kinase modulation
Fused heterocycles	Quinoline, benzimidazole, triazolopyrimidine	Rigidity and extended aromatic interactions	Improved affinity and pathway selectivity

Note: H-bonding: hydrogen bonding

Rational and Structure-Based Design of Bioactive Heterocycles

The development of heterocyclic compounds has been revolutionized by rational drug design; the process of heterocyclic drug design has been shifted from an empirical synthetic approach to a mechanism-oriented approach guided by the molecular structure, target biology and measurable structure–activity relationships. Structure-based drug design is based on the experimentally determined or computed 3D structure of the target to identify binding cavities, essential residues, conserved interaction motifs and solvent-accessible regions for ligand optimization [33]. Heterocyclic scaffolds are especially suitable for this strategy because the position of their heteroatoms, ring systems and orientations of their substituents can be systematically changed to optimize complementary interactions in a defined binding environment.

Protein kinases are a representative example of structure-based design of heterocycles. The majority of kinase inhibitors use a nitrogen-containing heterocycle that can be involved in hydrogen bonding with the hinge residues of adenosine triphosphate. Modification of peripheral substituents can yield enhanced potency and kinase selectivity through structural modification to extend interactions into hydrophobic pockets or allosteric sites [34]. This is also true for epigenetic enzymes, nuclear receptors, transcription factors, and DNA repair proteins.

Molecular docking is often used at the early stage of the process to generate hypotheses from the beginning of the study by predicting the orientation of the ligand and potential favorable protein–ligand interactions. However, the docking scores

alone cannot be considered a reliable marker of biological potency, as they only partially cover the effects of the solvent, protein flexibility, entropy, and target accessibility within the cell [35]. Complementary to docking, molecular dynamics simulations can also be used to evaluate the temporal stability of ligand–target complexes and to discover conformational transitions that accompany binding [36]. Experimental structural information from X-ray crystallography, NMR spectroscopy, or biophysical binding assays is still fundamental to validate computational predictions. Structural biology, medicinal chemistry, and molecular modeling and biological assay therefore provide a comprehensive platform for the design of selective and pathway-specific heterocyclic modulators with better affinity [37]. The structure-based workflow for designing and optimizing bioactive heterocycles is shown in Figure 2.



Figure 2. Rational and Structure-Based Design of Bioactive Heterocycles

Structural and Spectroscopic Characterization of Designed Heterocycles

Before understanding the biological activity of a new compound designed as a heterocycle, rigorous structural characterization is required to establish its chemical identity, purity, connectivity, and stereochemical integrity. FTIR can yield data on characteristic functional groups such as carbonyl, hydroxyl, amino, nitrile, and heteroatoms, and it can help to confirm successful synthetic transformations [38]. In highly aromatic or chromophoric heterocyclic structures, UV–visible spectroscopy can also be used to further characterize conjugated systems and electronic transitions.

Nuclear magnetic resonance spectroscopy is one of the most useful techniques for molecular characterization. Proton nuclear magnetic resonance (^1H NMR) gives information about proton environments, chemical shifts, multiplicity, coupling constants, and relative integration, while carbon-13 nuclear magnetic resonance (^13C NMR) allows for assignment of carbon environments across the heterocyclic framework [39]. The proton-proton and proton-carbon connectivity, or the complex substitution pattern or stereochemical relations, can be established using two-dimensional techniques like correlation spectroscopy, heteronuclear single quantum coherence, heteronuclear multiple bond correlation, and nuclear Overhauser effect spectroscopy.

Mass spectrometry offers complementary information on molecular mass and fragmentation pattern, and high-resolution mass spectrometry can be used to determine the elemental composition and molecular formula [40]. Elemental analysis can offer further confirmation of the proportions of the elements C, H, N, S, or others. For compounds with stereogenic centers, chiral chromatography and circular dichroism can help to determine the difference between enantiomers as well as the absolute or relative stereochemistry [41]. In structure–activity relationship studies, such as those aimed at determining molecular potency or pathway selectivity, it is especially important to have comprehensive characterization, as incorrect assignments may result in erroneous conclusions about molecular potency or pathway selectivity. Complementary analytical approaches can thus provide a solid foundation for further computational modeling, target-binding studies, cellular assays, and mechanistic investigations [42]. Table 2 lists the main computational and experimental methods employed for the design and molecular characterization of bioactive heterocyclic compounds.

Table 2. Molecular Design and Characterization Approaches for Bioactive Heterocycles

Approach	Primary purpose	Major information obtained
Structure-based design	Optimize target-specific interactions	Binding orientation and key residues

Molecular docking	Predict ligand–target binding	Binding pose and interaction profile
Molecular dynamics	Evaluate complex stability	Structural flexibility and interaction persistence
NMR spectroscopy	Confirm molecular structure	Connectivity and chemical environment
HRMS	Confirm molecular mass/formula	Accurate molecular composition
X-ray crystallography	Determine three-dimensional structure	Molecular geometry and binding architecture

Note: HRMS: high-resolution mass spectrometry; NMR: nuclear magnetic resonance

From Ligand–Target Recognition to Regulation of Gene Expression

Molecular recognition is the first chemical step in the pharmacological modulation of genetic signaling by heterocyclic compounds, and ultimately relies on the transmission of this interaction through cell signaling networks. A heterocyclic molecule may bind a receptor, an enzyme, a kinase, a transcriptional regulator, or an epigenetic protein, which can change the catalytic activity, the shape of the protein, the formation of complexes, the localization of the protein, or the post-translational modification of the protein [43]. These proximal molecular events can then lead to changes in phosphorylation cascades and second-messenger systems, which alter the activity of transcription factors and program of gene-expression.

A well-documented example of this sequence is the receptor tyrosine kinases. Upon activation by a ligand, the receptor normally undergoes dimerisation and phosphorylation, which then leads to the recruitment of other proteins that activate pathways such as the RAS/RAF/MEK/ERK pathway and the PI3K/AKT/mTOR pathway. The inhibition of the receptor or downstream kinase is a mechanism that prevents these cascades and can inhibit proliferation, survival, angiogenesis, and metabolic adaptation transcriptional programs—all of which are important for cancer—by heterocyclic inhibitors that inhibit the activity of the receptor or the downstream kinases [44]. Other intracellular regulatory proteins such as modulators of Janus kinases, Src-family kinases, cyclin-dependent kinases, and others are similarly regulated.

Signaling at the nuclear level can be altered by heterocyclic compounds, too. The genes related to these processes can be altered through the modulation of transcription factors like STAT proteins, NF-κB, HIF-1α, p53, MYC, β-catenin, and NRF2 [45]. Epigenetic modulators can also affect chromatin accessibility and transcribability by affecting histone modifications or DNA methylation [46]. Biological effects are a consequence of a multi-step process that includes target engagement, signaling disruption, transcriptional changes, and phenotypic changes. To prove this sequence, it is essential to demonstrate this sequence as well as to distinguish it from the compounds that cause a general cell effect, and to give a more solid foundation for the development of therapeutics [47].

Major Genetic Signaling Pathways Targeted by Heterocyclic Compounds

Heterocyclic compounds have the potential to regulate multiple cross-talking signaling pathways involved in cellular proliferation, survival, differentiation, inflammation, metabolism, and stress responses. The PI3K/AKT/mTOR pathway is a key pathway of therapeutic interest due to its role in aberrant activation leading to cell growth, metabolic adaptation, protein synthesis, and apoptosis resistance. Heterocyclic inhibitors targeting PI3K, AKT and/or mTOR may inhibit downstream signaling and alter survival and proliferation-mediated transcriptional programs [46]. The RAS/RAF/MEK/ERK pathway is also involved in growth factor signalling, and heterocyclic kinase inhibitors may block the sequential phosphorylation events that mediate growth factor-dependent nuclear transcriptional signals from membrane receptors [47].

Cytokine and growth-factor receptors are coupled to gene transcription via the JAK/STAT pathway. Targeting the JAK-family proteins or blocking STAT activity has been shown to decrease pathological inflammatory, proliferative, and immune processes [48]. Another target of interest is wnt/β-catenin signaling pathways, which can be activated by the abnormal stabilization and nuclear translocation of β-catenin, leading to the activation of transcriptional programs regulating stemness, proliferation, and tumor progression. Therefore, drugs that interfere with any of the pathway components or β-catenin-associated transcription have the potential to be therapeutic agents.

NF-κB signaling plays a key role in inflammation, immunity, cellular stress, and survival, whereas p53-related signaling controls DNA damage responses, cell-cycle arrest, senescence, and apoptosis. Modulators of these networks that are heterocyclic could modulate the balance between programmed death and cellular survival [49]. Other pathways, such as the TGF-β/SMAD, Notch, Hedgehog, Hippo/YAP–TAZ, HIF, NRF2/KEAP1, AMPK, and cGAS–STING pathways, also expand the molecular space that is available for heterocyclic drug design [50]. There is extensive crosstalk between pathways, and successful modulation of any pathway within the therapeutic window will depend on assessment of both the inhibition of the primary pathway and the compensatory responses of the network. A summary of major genetic signaling pathways that are modulated by heterocyclic compounds is provided in Table 3.

Table 3. Major Genetic Signaling Pathways Modulated by Heterocyclic Compounds

Signaling pathway	Principal biological function	Potential effect of modulation
PI3K/AKT/mTOR	Cell growth, metabolism, survival	Reduced proliferation and survival signaling
RAS/RAF/MEK/ERK	Proliferation and differentiation	Suppression of mitogenic signaling
JAK/STAT	Cytokine signaling and transcription	Reduced inflammatory and proliferative responses

Wnt/β-catenin	Stemness and cell proliferation	Suppression of aberrant transcription
NF-κB	Inflammation and immune regulation	Reduced inflammatory gene expression
p53	DNA-damage response and apoptosis	Restoration of cell-cycle control and apoptosis

Note: AKT: protein kinase B; JAK: Janus kinase; MEK: mitogen-activated protein kinase kinase; mTOR: mammalian target of rapamycin; NF-κB: nuclear factor kappa B; PI3K: phosphoinositide 3-kinase; STAT: signal transducer and activator of transcription

Limitations and Future Directions

The review has some limitations as there is heterogeneity in molecular targets, biological endpoints, experimental models, and heterocyclic scaffolds, making it difficult to directly compare studies. The available evidence consists largely of computational and in vitro studies, with fewer in vivo or clinical studies available. Molecular docking and molecular dynamics might not adequately simulate the complexity and/or prove functional target engagement within the cell. Therapeutic translation may also be further limited by limited specificity, off-target toxicity, low solubility, poor pharmacokinetics, pathway redundancy, and compensatory signaling.

Integrated design approaches, integrating structural biology, medicinal chemistry, artificial intelligence and multi-omics profiling should be emphasized as areas for future research to enhance target specificity and to enable network-level responses to be predicted. Single-cell and spatial omics can aid in the identification of context-dependent signaling impact(s) and responsive patient subgroups. The functional validation, biomarker-guided drug development, targeted protein degradation, RNA-directed small molecules, and precision delivery systems are other possibilities that deserve more attention with CRISPR technology. These strategies can be useful for the design of safer, more selective, and clinically translatable heterocyclic modulators.

CONCLUSION

The review focuses on the significant potential of bioactive heterocyclic compounds in the modulation of genetic signaling pathways and the strong correlation between molecular structure, target recognition, and biological response. Nitrogen-, oxygen-, and sulfur-containing, fused, and polycyclic heterocycles offer a diverse range of scaffolds for the development of inhibitors targeting kinases, transcription factors, epigenetic regulators, and nucleic acid-associated proteins and other signaling pathways that play a role in disease progression. Recent developments in structure-based drug design, molecular docking, molecular dynamics, spectroscopy, crystallography, and multi-omics analysis have enhanced the molecular characterization and mechanistic understanding of these compounds. Further issues to address are pathway redundancy, off-target effects, resistance, low bioavailability, and lack of translation of computational predictions to biological efficacy. The incorporation of AI, systems biology, CRISPR-based validation, biomarker-driven methods, and precision delivery mechanisms could propel next-generation heterocyclic therapeutics to the fore. This chemical-signaling integration approach can help to develop more selective, mechanistically validated, and clinically relevant modulators for precision therapeutic applications.

REFERENCES

1. Egbujor MC, Tucci P, Onyeije UC, Emeruwa CN, Saso L. NRF2 activation by nitrogen heterocycles: a review. Molecules. 2023 Mar 18;28(6):2751.
2. Mustafa YF. Bioactive coumarins: bioorganic strategies for targeting enzymes, receptors, and DNA. Russian Journal of Bioorganic Chemistry. 2025 Oct;51(5):2304-35.
3. El-Sayed NN, Krayem N, Derbala HA, Kamal S, Bukhari SN, El-Ashrey MK, Almarhoon ZM, Soliman Alterary S, Ben Bacha A. New nitrogen-, oxygen-, and sulfur-containing heterocyclic compounds as anti-colon cancer agents: Synthesis, multitargeted evaluations, molecular docking simulations and ADMET predictions. Pharmaceuticals. 2025 May 27;18(6):801.
4. Noser AA, Abdelmonsef AH, Salem MM. Design, synthesis and molecular docking of novel substituted azepines as inhibitors of PI3K/Akt/TSC2/mTOR signaling pathway in colorectal carcinoma. Bioorganic Chemistry. 2023 Feb 1;131:106299.
5. Bhusare NI, Kumar MA. A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases. Oncology Research. 2024 Apr 23;32(5):849.
6. Laxmikeshav K, Kumari P, Shankaraiah N. Expedition of sulfur-containing heterocyclic derivatives as cytotoxic agents in medicinal chemistry: A decade update. Medicinal Research Reviews. 2022 Jan;42(1):513-75.
7. Kapoor K, Kaur N, Sohal HS, Kaur M, Singh K, Kumar A. Drugs and their mode of action: a review on sulfur-containing heterocyclic compounds. Polycyclic Aromatic Compounds. 2025 Jan 2;45(1):136-75.
8. Kumar N, Goel N. Heterocyclic compounds: importance in anticancer drug discovery. Anti-Cancer Agents in Medicinal Chemistry-Anti-Cancer Agents). 2022 Nov 1;22(19):3196-207.
9. Petri GL, Spano V, Spatola R, Holl R, Raimondi MV, Barraja P, Montalbano A. Bioactive pyrrole-based compounds with target selectivity. European journal of medicinal chemistry. 2020 Dec 15;208:112783.
10. Gutiérrez-Rodelo C, Martínez-Tolibia SE, Morales-Figueroa GE, Velázquez-Moyado JA, Olivares-Reyes JA, Navarrete-Castro A. Modulating cyclic nucleotides pathways by bioactive compounds in combatting anxiety and depression disorders. Molecular Biology Reports. 2023 Sep;50(9):7797-814.
11. Laraia L, Robke L, Waldmann H. Bioactive compound collections: from design to target identification. Chem. 2018 Apr 12;4(4):705-30.

12. Mir MA, Banik BK. Heterocyclic phytochemicals as anticancer agents. Current Topics in Medicinal Chemistry. 2025 Feb;25(5):533-53.
13. Hassan R, Mohi-Ud-Din R, Dar MO, Shah AJ, Mir PA, Shaikh M, Pottoo FH. Bioactive heterocyclic compounds as potential therapeutics in the treatment of gliomas: a review. Anti-Cancer Agents in Medicinal Chemistry-Anti-Cancer Agents). 2022 Feb 1;22(3):551-65.
14. Salah AR. Heterocyclic compounds in modern drug design: synthetic strategies and biological targets. Shorouk Academy–Department of Engineering. 2025 Oct 4:1-5.
15. Ghadwal RS. Tuning the electronic properties of main-group species by N-heterocyclic vinyl (NHV) scaffolds. Accounts of Chemical Research. 2022 Jan 18;55(3):457-70.
16. Qie B, Wang Z, Jiang J, Zhang Z, Jacobse PH, Lu J, Li X, Liu F, Alexandrova AN, Louie SG, Crommie MF. Synthesis and characterization of low-dimensional N-heterocyclic carbene lattices. Science. 2024 May 24;384(6698):895-901.
17. Ogawa T, Sinha N, Pfund B, Prescimone A, Wenger OS. Molecular design principles to elongate the metal-to-ligand charge transfer excited-state lifetimes of square-planar nickel (ii) complexes. Journal of the American Chemical Society. 2022 Nov 23;144(48):21948.
18. Kerru N, Gummidi L, Maddila S, Gangu KK, Jonnalagadda SB. A review on recent advances in nitrogen-containing molecules and their biological applications. Molecules. 2020 Apr 20;25(8):1909.
19. Frank É, Szőllősi G. Nitrogen-containing heterocycles as significant molecular scaffolds for medicinal and other applications. Molecules. 2021 Jul 30;26(15):4617.
20. Majhi S, Saha I. Visible light-promoted synthesis of bioactive N, N-heterocycles. Current Green Chemistry. 2022 Dec 1;9(3):127-44.
21. Biswas T, Mittal RK, Sharma V, Kanupriya, Mishra I. Nitrogen-fused heterocycles: empowering anticancer drug discovery. Medicinal Chemistry. 2024 May 1;20(4):369-84.
22. Li Z, Ma W, Gu L, Xie J, Yang K, Lin S. Recent developments in the utilization of pyridones as privileged scaffolds in drug discovery. Expert Opinion on Drug Discovery. 2025 Jul 3;20(7):873-89.
23. Makhova NN, Belen'kii LI, Gazieva GA, Dalinger IL, Konstantinova LS, Kuznetsov VV, Kravchenko AN, Krayushkin MM, Rakitin OA, Starosotnikov AM, Fershtat LL. Progress in the chemistry of nitrogen-, oxygen-and sulfur-containing heterocyclic systems. Russian Chemical Reviews. 2020 Jan 1;89(1):55-124.
24. Zheng Y, Li J, Wu W, Qi C, Jiang H. Oxygen-, nitrogen-, and sulfur-containing heterocycles: recent advances in De Novo synthesis and prospect. Organic Process Research & Development. 2024 Jul 13;28(8):2988-3025.
25. Nagesh Khadri MJ, Shashikumar U, Tsai PC, Manjappa KB, Ponnusamy VK, Khanum SA. Nitrogen, Oxygen, and Sulphur Heterocycles as Potent Anti-Inflammatory Agents: Insight Into the Synthetic Routes. ChemistrySelect. 2025 Mar;10(9):e202403824.
26. Ghosh T, Santra S, Zyryanov GV, Ranu BC. Recent Developments on the Synthesis of Oxygen-and Sulfur-containing Heterocycles and their Derivatives under Visible Light Induced Reactions. Current Topics in Medicinal Chemistry. 2025 Jan;25(1):124-40.
27. El-Sayed NN, Krayem N, Derbala HA, Kamal S, Bukhari SN, El-Ashrey MK, Almarhoon ZM, Soliman Alterary S, Ben Bacha A. New nitrogen-, oxygen-, and sulfur-containing heterocyclic compounds as anti-colon cancer agents: Synthesis, multitargeted evaluations, molecular docking simulations and ADMET predictions. Pharmaceuticals. 2025 May 27;18(6):801.
28. Zheng L, Hua R. Recent advances in construction of polycyclic natural product scaffolds via one-pot reactions involving alkyne annulation. Frontiers in Chemistry. 2020 Oct 15;8:580355.
29. Cai X, Song X, Yang X, Zhang X, Fan X. A divergent construction of fused and bridged carbo-/heterocyclic scaffolds via cascade reactions of aryl azomethine imines with vinyl cyclic carbonates. Organic Chemistry Frontiers. 2023 Feb 14;10(4):1015-21.
30. Tao X, Han H, Jeong J, Kim D, Hong S. Transformation of pyridines into 2D and 3D fused bicyclic heterocycles. Journal of the American Chemical Society. 2025 Jun 6;147(24):21143-52.
31. Li J, Yang Y, Dai Z, Chen S, Xiong S, Li G, Zeng L, Cui S. Bridged scaffold editing of carbocycles and heterocycles. Nature Communications. 2026 May 19.
32. Ciccolini C, Mari G, Gatti FG, Gatti G, Giorgi G, Mantellini F, Favi G. Synthesis of polycyclic fused indoline scaffolds through a substrate-guided reactivity switch. The Journal of Organic Chemistry. 2020 Aug 12;85(17):11409.
33. Nath R, Ashique S, Nehra B, Debnath I, Ghosh S, Chawla PA, Al-Salem FM, Yasmin S, Hussain MS, Das L, Chakraborty A. Rational drug design and synthesis of novel bioactive molecules with oxygen heterocycles, including AChE and BChE inhibitory properties and SAR studies. Molecular Diversity. 2026 Mar 12:1-53.
34. Piemontese L, Tomás D, Hiremathad A, Capriati V, Candeias E, Cardoso SM, Chaves S, Santos MA. Donepezil structure-based hybrids as potential multifunctional anti-Alzheimer's drug candidates. Journal of enzyme inhibition and medicinal chemistry. 2018 Jan 1;33(1):1212-24.
35. Kostova I. "Rational Design and Synthesis of Bioactive Molecules". International Journal of Molecular Sciences. 2024 Sep 14;25(18):9927.
36. Khan S, Iqbal T, Hussain R, Khan Y, Ullah H, Jamal U, Iqbal R, Alfarraj S, Alharbi SA. Structure based design, synthesis of novel fused triazole-thiazole derivatives and their comparative study on Alzheimer disease along with in silico modeling. Results in Chemistry. 2024 Jun 1;8:101590.
37. Sarma RK, Choudhury AA, Adhikari N. A Review on Microwave-Assisted Synthesis of Fused N-Containing Bioactive Heterocyclic Molecules. ChemistrySelect. 2026 Jan;11(1):e04973.

38. Dinari M, Gharahi F, Asadi P. Synthesis, spectroscopic characterization, antimicrobial evaluation and molecular docking study of novel triazine-quinazolinone based hybrids. Journal of Molecular Structure. 2018 Mar 15;1156:43-50.
39. Mallikarjuna NM, Keshavayya J. Synthesis, spectroscopic characterization and pharmacological studies on novel sulfamethaxazole based azo dyes. Journal of King Saud University-Science. 2020 Jan 1;32(1):251-9.
40. BHARDWAJ A, AGRAWAL OP. CHARACTERIZATION OF NOVEL HETROCYCLIC MOLECULES CONTAINING NITROGEN. Quantum Journal of Medical and Health Sciences. 2025 Oct 31;4(5):1-0.
41. Mazrouei M, Pordel M, Davoodnia A, Beyramabadi SA. Synthesis and characterization of new purple and green heterocyclic dyes for dye-sensitized solar cells. Journal of Molecular Structure. 2024 Nov 5;1315:138814.
42. Bai W, Yang P, Liu H, Zou Y, Wang X, Yang Y, Gu Z, Li Y. Boosting the optical absorption of melanin-like polymers. Macromolecules. 2022 Apr 27;55(9):3493-501.
43. Chong S, Dugast-Darzacq C, Liu Z, Dong P, Dailey GM, Cattoglio C, Heckert A, Banala S, Lavis L, Darzacq X, Tjian R. Imaging dynamic and selective low-complexity domain interactions that control gene transcription. Science. 2018 Jul 27;361(6400):eaar2555.
44. Xu X, Qi LS. A CRISPR–dCas toolbox for genetic engineering and synthetic biology. Journal of molecular biology. 2019 Jan 4;431(1):34-47.
45. Chen R, Zou J, Chen J, Zhong X, Kang R, Tang D. Pattern recognition receptors: function, regulation and therapeutic potential. Signal Transduction and Targeted Therapy. 2025 Jul 11;10(1):216.
46. Henley MJ, Koehler AN. Advances in targeting 'undruggable'transcription factors with small molecules. Nature Reviews Drug Discovery. 2021 Sep;20(9):669-88.
47. Bushweller JH. Targeting transcription factors in cancer—from undruggable to reality. Nature Reviews Cancer. 2019 Nov;19(11):611-24.
48. Egbujor MC, Tucci P, Onyeije UC, Emeruwa CN, Saso L. NRF2 activation by nitrogen heterocycles: a review. Molecules. 2023 Mar 18;28(6):2751.
49. Bhusare NI, Kumar MA. A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases. Oncology Research. 2024 Apr 23;32(5):849.
50. Abd El-Aleam RH, George RF, Georgey HH, Abdel-Rahman HM. Bacterial virulence factors: a target for heterocyclic compounds to combat bacterial resistance. RSC advances. 2021 Nov 19;11(58):36459-82.